These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 24918522)

  • 1. Industry withdrawal from psychiatric medication development.
    Klein DF; Glick ID
    Braz J Psychiatry; 2014 Sep; 36(3):259-61. PubMed ID: 24918522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mind how you go.
    Nature; 2013 Oct; 502(7470):141. PubMed ID: 24137753
    [No Abstract]   [Full Text] [Related]  

  • 3. An analysis of original research contributions toward FDA-approved drugs.
    Patridge EV; Gareiss PC; Kinch MS; Hoyer DW
    Drug Discov Today; 2015 Oct; 20(10):1182-7. PubMed ID: 26113307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Should financial incentives be used to differentially reward 'me-too' and innovative drugs?
    Pekarsky B
    Pharmacoeconomics; 2010; 28(1):1-17. PubMed ID: 20014872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Pressing Need for Pharmacotherapy Development to Treat Drug Addiction: An Editorial from a Legal Perspective.
    Andraka-Christou B
    Int Rev Neurobiol; 2016; 126():15-38. PubMed ID: 27055610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discontinued drugs in 2010: oncology drugs.
    Williams R
    Expert Opin Investig Drugs; 2011 Nov; 20(11):1479-96. PubMed ID: 21955127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medications development for substance-use disorders: contextual influences (dis)incentivizing pharmaceutical-industry positioning.
    Janero DR
    Expert Opin Drug Discov; 2014 Nov; 9(11):1265-79. PubMed ID: 25162124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CNS Drug Development: Lessons Learned Part 3: Psychiatric and Central Nervous System Drugs Developed Over the Last Decade-Implications for the Field.
    Preskorn SH
    J Psychiatr Pract; 2017 Sep; 23(5):352-360. PubMed ID: 28961664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug development research: diabetes favored over cardiovascular disease?
    Suckling K
    Curr Opin Investig Drugs; 2009 Mar; 10(3):217-9. PubMed ID: 19333877
    [No Abstract]   [Full Text] [Related]  

  • 10. Opportunities and challenges in the discovery of new central nervous system drugs.
    Krause JE; Chenard BL
    Ann N Y Acad Sci; 2008 Nov; 1144():243-50. PubMed ID: 19076381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New directions for drug discovery.
    Spedding M
    Dialogues Clin Neurosci; 2006; 8(3):295-301. PubMed ID: 17117611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CNS drug development in Europe--past progress and future challenges.
    Nutt DJ; Attridge J
    Neurobiol Dis; 2014 Jan; 61():6-20. PubMed ID: 23685094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes.
    Lienhardt C; Vernon A; Raviglione MC
    Curr Opin Pulm Med; 2010 May; 16(3):186-93. PubMed ID: 20216421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trial watch: Clinical trial cycle times continue to increase despite industry efforts.
    Martin L; Hutchens M; Hawkins C
    Nat Rev Drug Discov; 2017 Mar; 16(3):157. PubMed ID: 28184041
    [No Abstract]   [Full Text] [Related]  

  • 15. Vas Narasimhan.
    Narasimhan V; Mullard A
    Nat Rev Drug Discov; 2016 Jan; 15(1):10-1. PubMed ID: 26718275
    [No Abstract]   [Full Text] [Related]  

  • 16. 2011 in reflection.
    Mullard A
    Nat Rev Drug Discov; 2012 Jan; 11(1):6-8. PubMed ID: 22212664
    [No Abstract]   [Full Text] [Related]  

  • 17. An improved approach to measuring drug innovation finds steady rates of first-in-class pharmaceuticals, 1987-2011.
    Lanthier M; Miller KL; Nardinelli C; Woodcock J
    Health Aff (Millwood); 2013 Aug; 32(8):1433-9. PubMed ID: 23918488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ethical challenges in developing drugs for psychiatric disorders.
    Carrier F; Banayan D; Boley R; Karnik N
    Prog Neurobiol; 2017 May; 152():58-69. PubMed ID: 28268181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trial watch: Opportunities and challenges of the 2016 target landscape.
    Lafferty-Whyte K; Mormeneo D; Del Fresno Marimon M
    Nat Rev Drug Discov; 2017 Jan; 16(1):10-11. PubMed ID: 27980340
    [No Abstract]   [Full Text] [Related]  

  • 20. The value of drug repositioning in the current pharmaceutical market.
    Tobinick EL
    Drug News Perspect; 2009 Mar; 22(2):119-25. PubMed ID: 19330170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.